FABBIANI MASSIMILIANO

Massimiliano
Fabbiani
Professore Associato

Presentation

Massimiliano Fabbiani is Associate Professor of Infectious Diseases at the Department of Medical Biotechnologies of the University of Siena. His research activity is mainly focused on HIV infection and antiretroviral therapy. In particular, he has participated in clinical trials on antiretroviral therapy and has conducted studies on the efficacy and tolerability of antiretroviral therapy, on the clinical pharmacology of antiretroviral drugs, on the epidemiology and resistance mechanisms of HIV, on adherence to therapy and on comorbidities during HIV infection (with a particular focus on HIV-related neurocognitive disorders). He has also studied the response to vaccinations (anti-influenza, anti-SARS-CoV-2, anti-pneumococcus) in subjects with and without HIV infection. Among the topics covered by his research activities are also infections by hepatitis viruses (HAV, HBV, HCV), SARS-CoV-2 infection, bacterial and fungal infections.

Office hours

Every day by appointment.

Policlinico Le Scotte, IV lotto, piano 0

Contacts

0577233461 [int.3461]

Curriculum Vitae

Teaching activities

Completion accademic year: 2026/2027

Course year: 1 First cycle degree (DM 270) ENVIRONMENT AND WORKPLACE PREVENTION TECHNIQUES A.Y. 2026/2027
Course year: 4 Full cicle (6 years) MEDICINA E CHIRURGIA A.Y. 2023/2024

Completion accademic year: 2025/2026

Course year: 1 First cycle degree (DM 270) ENVIRONMENT AND WORKPLACE PREVENTION TECHNIQUES A.Y. 2025/2026
Course year: 4 Full cicle (6 years) MEDICINE AND SURGERY A.Y. 2022/2023

Completion accademic year: 2024/2025

Research

Ultime pubblicazioni:

  • Vergori, A., Cervo, A., Roen, A., Gagliardini, R., Clemente, T., Mazzotta, V., et al. (2026). Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort. OPEN FORUM INFECTIOUS DISEASES, 13(5) [10.1093/ofid/ofag250]. - view more
  • Ciccullo, A., Iannone, V., Giacomelli, A., Baldin, G., Lagi, F., Sambo, M., et al. (2026). Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort. AIDS, 40(7), 962-966 [10.1097/qad.0000000000004468]. - view more
  • Ciccullo, A., Baldin, G., Cervo, A., Oreni, L., Mazzitelli, M., Gasparro, G., et al. (2026). ‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(6) [10.1093/jac/dkag172]. - view more
  • Clemente, T., Torkjazi, G., Capra, N., Gagliardini, R., Cattelan, A.M., Lolatto, R., et al. (2026). Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(1) [10.1093/jac/dkaf415]. - view more
  • Micheli, G., Mondi, A., Roen, A., Taramasso, L., Luchetti, I., Mazzotta, V., et al. (2026). Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 165 [10.1016/j.ijid.2026.108437]. - view more